United Kingdom-based AstraZeneca's Imfinzi (durvalumab) has improved overall survival (OS) in patients with earlier untreated extensive-stage small cell lung cancer (SCLC) in the phase III Caspian study, it was reported yesterday.
The product along with four cycles of standard-of-care chemotherapy, indicated a statistically-significant and clinically-meaningful improvement in OS against standard-of-care, including up to six cycles of chemotherapy and optional prophylactic cranial irradiation.
It is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80. It is intended to help counter the tumour's immune-evading tactics and releases the inhibition of immune responses.
Caspian is a randomised, open-label, multi-centre, global and phase III study in the first-line treatment of patients with extensive-stage SCLC. With OS as the primary endpoint, the study is being carried out in over 200 centres across 22 countries, including the US, Europe, South America, Asia and the Middle East.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review